Science Explorer Back to mapMap
Discussion
Topic · Pulmonary and Respiratory Medicine

Advanced Breast Cancer Therapies

Advanced Breast Cancer Therapies is a research topic within Pulmonary and Respiratory Medicine. Science Explorer counts 18k research works in it since 1952. 11.2% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as palbociclib, letrozole, ribociclib, and abemaciclib, in the treatment of hormone receptor-positive metastatic breast cancer. The papers cover various aspects including clinical trials, mechanisms of action, therapeutic resistance, combination strategies, and potential biomarkers.

  • CDK4/6 Inhibitors
  • Breast Cancer
  • Palbociclib
  • Letrozole
  • Ribociclib
  • Abemaciclib
  • Hormone Receptor-Positive
  • Metastatic Breast Cancer
  • Cell Cycle Control
  • Therapeutic Resistance
Research works
18k
fractional, since 1952
In the world top 10%
2k
per year above
Top-10% rate
11.2%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+27%
the tick is no change
Largest producer
United States
42% of the 10 largest, 2022-now
Advanced Breast Cancer Therapies

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Advanced Breast Cancer Therapies research?

By volume, the United States and China publish the most (2.2k and 1.1k works in 2022-now).

By volume, 2022-now

  1. 1 United States 2.2k works
  2. 2 China 1.1k works
  3. 3 Italy 331 works
  4. 4 Spain 276 works
  5. 5 India 274 works
  6. 6 Germany 253 works
  7. 7 Japan 243 works
  8. 8 United Kingdom 236 works
  9. 9 France 220 works
  10. 10 South Korea 146 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 41.6%China: 20.9%Italy: 6.3%Spain: 5.2%6 others listed: 26.0%42%largest
United States2,196 · 41.6%China1,105 · 20.9%Italy331 · 6.3%Spain276 · 5.2%6 others listed1,371 · 26.0%

Shares of the rows listed above, not of the whole node.

Which institutions lead Advanced Breast Cancer Therapies research?

By volume in 2022-now, Harvard University publishes the most Advanced Breast Cancer Therapies research, followed by The University of Texas MD Anderson Cancer Center and University of North Carolina at Chapel Hill.

By volume, 2022-now

  1. 1 Harvard UniversityUnited States 146 works
  2. 2 The University of Texas MD Anderson Cancer CenterUnited States 96 works
  3. 3 University of North Carolina at Chapel HillUnited States 58 works
  4. 4 Mayo ClinicUnited States 54 works
  5. 5 Sun Yat-sen UniversityChina 52 works
  6. 6 Memorial Sloan Kettering Cancer CenterUnited States 48 works
  7. 7 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 45 works
  8. 8 AstraZeneca (United Kingdom)United Kingdom 35 works
  9. 9 University of California, San FranciscoUnited States 34 works
  10. 10 Pfizer (United States)United States 32 works

Who are the leading researchers in Advanced Breast Cancer Therapies?

The most-cited researchers publishing on Advanced Breast Cancer Therapies include Ahmedin Jemal, Guido Kroemer and Bert Vogelstein.

  1. 1 Ahmedin Jemal United States 761k citations
  2. 2 Guido Kroemer France 386k citations
  3. 3 Bert Vogelstein United States 373k citations
  4. 4 Gad A. Getz United States 364k citations
  5. 5 Elaine R. Mardis United States 346k citations
  6. 6 Hermann Brenner Germany 343k citations
  7. 7 Jun Wang China 340k citations
  8. 8 Richard A. Gibbs United States 292k citations
  9. 9 Matthew M. Meyerson United States 280k citations
  10. 10 Hagop M. Kantarjian United States 273k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Advanced Breast Cancer Therapies?

The most cited paper in Advanced Breast Cancer Therapies is "Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies" (Brian David Lehmann, Joshua A. Bauer, Xi Chen et al., 2011), with 5,662 citations. Next come "Breast Cancer Treatment" (5,015) and "Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer" (4,641).

Most cited papers
#PaperReleasedCitations
1 Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies Brian David Lehmann, Joshua A. Bauer, Xi Chen et al. · Journal of Clinical Investigation Open access 10 Jun 2011 5,662
2 Breast Cancer Treatment Adrienne Gropper Waks, Eric P. Winer · JAMA 22 Jan 2019 5,015
3 Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer Massimo Cristofanilli, George Thomas Budd, Matthew J. Ellis et al. · New England Journal of Medicine Open access 18 Aug 2004 4,641
4 Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer Peter Schmid, Sylvia Adams, Hope S. Rugo et al. · New England Journal of Medicine Open access 20 Oct 2018 4,469
5 Triple-Negative Breast Cancer William David Foulkes, Ian E. Smith, Jorge Sergio Reis-Filho · New England Journal of Medicine 10 Nov 2010 4,277
All 100 most cited papers, with filters and sorting

Where is Advanced Breast Cancer Therapies research done?

The largest centres of Advanced Breast Cancer Therapies research in 2022-now are New York (United States), Beijing (China), Boston (United States) and Houston (United States).

Largest cities, 2022-now

  1. 1 New YorkUnited States 167 works
  2. 2 BeijingChina 139 works
  3. 3 BostonUnited States 139 works
  4. 4 HoustonUnited States 133 works
  5. 5 ShanghaiChina 115 works
  6. 6 SeoulSouth Korea 91 works
  7. 7 GuangzhouChina 81 works
  8. 8 LondonUnited Kingdom 80 works
  9. 9 BarcelonaSpain 78 works
  10. 10 MilanItaly 72 works
See Advanced Breast Cancer Therapies on the map

Where is the best place to study Advanced Breast Cancer Therapies?

Among universities, judged by research, Harvard University, University of Milan and Cornell University score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%30%mean 21.43%fractional works in this field (log) →share of work in the world top 10% →University of Washin…University of MilanHarvard UniversityCornell University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 84.620.0%7.7×146 +10.9%
2University of MilanItaly 62.023.9%3.8×15 +80.7%
3Cornell UniversityUnited States 59.819.1%3.5×27 +4.9%
4University of WashingtonUnited States 58.627.6%1.4×10 +21.9%
5University of California, San FranciscoUnited States 57.816.3%7.9×34 +4.5%
6University of UlsanSouth Korea 57.524.8%7.2×8 +30.6%
7Columbia UniversityUnited States 56.521.8%2.5×16 +36.3%
8China Pharmaceutical UniversityChina 56.224.7%8.2×11 +79.4%
9Sun Yat-sen UniversityChina 55.512.9%4.2×52 +54.5%
10McGill UniversityCanada 55.423.2%2.4×14 +8.5%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Advanced Breast Cancer Therapies, country by country

Is Advanced Breast Cancer Therapies research growing?

Output in 2022-2025 was 27% higher than in 2018-2021, peaking in 2026. The fastest-growing topics are Advanced Breast Cancer Therapies.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Advanced Breast Cancer Therapies as a percentage of every work published that year, 0.024% in 2024.

still counting0.010%0.020%0.030%Advanced Breast Cancer Therapies0.025% in 202519801990200020102020

Fractional works of Advanced Breast Cancer Therapies over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Advanced Breast Cancer Therapies10.3% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Advanced Breast Cancer Therapies. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.